Eli Lilly Secures $2.75B Exclusive AI Drug Development Pact
Eli Lilly has struck a $2.75 billion agreement with Insilico Medicine granting exclusive global rights to develop and sell AI-discovered drug candidates, with upfront payments and potential milestones and royalties. Insilico’s generative AI platform has produced 28 molecules, nearly half in clinical trials, potentially speeding Lilly’s research pipeline.
1. Deal Terms and Scope
Eli Lilly has expanded its partnership with Insilico Medicine via a master agreement valued at up to $2.75 billion, including an upfront payment and potential milestone and royalty payments. This deal grants Lilly exclusive global rights to develop and commercialize any AI-discovered therapies emerging from the collaboration.
2. Insilico's AI Pipeline
Insilico has leveraged generative AI to design more than 28 drug candidates, with nearly half already in clinical trials. These molecules span multiple therapeutic areas, potentially accelerating early-stage discovery and broadening Lilly’s development pipeline.
3. Strategic Rationale and Investment
Lilly is channeling revenue from its high-growth obesity franchise into artificial intelligence and high-performance computing to enhance drug discovery efficiency. This investment underscores the company’s commitment to integrating AI across research functions to drive future pipeline growth and cost savings.